Values First Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Values First Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11M	Buy	9,479 +82	+0.9%	+$8.23K	0.51%	62
2026 Q1	$868K	Sell	9,397 -7,027	-43%	-$661K	0.45%	62
2025 Q4	$1.3M	Sell	16,424 -2,288	-12%	-$164K	0.67%	46
2025 Q3	$1.37M	Sell	18,712 -920	-5%	-$58.5K	0.73%	46
2025 Q2	$999K	Buy	19,632 +1,514	+8%	+$67.4K	0.54%	55
2025 Q1	$818K	Sell	18,118 -1,722	-9%	-$81.2K	0.48%	56
2024 Q4	$820K	Sell	19,840 -3,885	-16%	-$162K	0.45%	62
2024 Q3	$925K	Buy	23,725 +3,971	+20%	+$158K	0.5%	54
2024 Q2	$675K	Sell	19,754 -1,654	-8%	-$43.4K	0.4%	67
2024 Q1	$538K	Buy	21,408 +4,668	+28%	+$128K	0.32%	93
2023 Q4	$494K	Sell	16,740 -21,179	-56%	-$641K	0.3%	108
2023 Q3	$1.2M	Buy	+37,919	New	+$1.04M	0.77%	41
2023 Q2	–	Sell	-8,497	Closed	-$204K	–	269
2023 Q1	$204K	Buy	+8,497	New	+$194K	0.13%	134

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Values First Advisors's MIRM Position: Q2 2026 in Review

Values First Advisors increased its Mirum Pharmaceuticals (MIRM) stake by 0.87% in Q2 2026, buying an estimated $8.23K and bringing the position to 9,479 shares worth $1.11M. The position accounts for 0.51% of the portfolio, ranked #62.

Values First Advisors first reported a position in MIRM in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.37M in Q3 2025. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

Values First Advisors held 9,479 shares of Mirum Pharmaceuticals worth $1.11M as of Q2 2026.
Values First Advisors bought 82 Mirum Pharmaceuticals shares in Q2 2026, an estimated $8.23K.
Mirum Pharmaceuticals made up 0.51% of Values First Advisors's portfolio in Q2 2026, its #62 holding.
Values First Advisors first reported a position in Mirum Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
Values First Advisors's Mirum Pharmaceuticals position peaked at $1.37M in Q3 2025.
327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Values First Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.